The following is excerpted from the question-and-answer section of the transcript.
(Questions from industry analysts are provided in full, but answers are omitted - download the transcript to see the full question-and-answer session)
Question: Sumant Satchidanand Kulkarni - Canaccord Genuity Corp., Research Division - Analyst
: I have a couple. On the price that you've set, can we assume very modest discounting of the 21,000 list, if any? And what might be a real-world
addressable peak share or utilization rate in the TDAPA period? And then I have a follow-up.
Question: Sumant Satchidanand Kulkarni - Canaccord Genuity Corp., Research Division - Analyst
: Yes, it's more a pipeline based thing. Is it fair to assume that notalgia paresthetica remains one of the more relatively challenging itch base indication
to target? And given that dynamic, how should we expect or read through anything you might learn from the upcoming oral KORSUVA data set
in MP to your own KORSUVA pivoted programs in pruritus in atopic dermatitis, for example?
Question: Daniel G. Wolle - JPMorgan Chase & Co, Research Division - Analyst
: You mentioned underreporting of pruritus by hemodialysis patients as one of the factors, including overlooking by physicians. So I'm trying to see
if there's any plans to get to those patients so that they're aware of treatment options possibly through some sort of DTC campaigns?
Question: Daniel G. Wolle - JPMorgan Chase & Co, Research Division - Analyst
: Okay. And then, will you be responsible financially for that type of marketing? Or will it be Vifor solely?
Question: Daniel G. Wolle - JPMorgan Chase & Co, Research Division - Analyst
: And then just to get a little bit color on the opportunity for notalgia paresthetica. You've outlined in prior presentations, the patient opportunity
to be around 1 million patients. Of those patients, how many have those have moderate to severe pruritus? And are this potentially addressable
by a treatment such as KORSUVA?
| 
